Applying a daily emollient on infants younger than aged 9 weeks reduced the risk for atopic dermatitis by 16% at 24 months ...

After underperforming the overall market for the past few years, large-cap pharmaceutical stocks may now be positioned to ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Q2 2025 Earnings Call Transcript July 16, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

SMX gains national spotlight as key player in securing defense supply chains – media recognition signals growing market relevance NEW YORK, NY / ACCESS Newswire / July 21, 2025 / A recent editorial ...